1. Pink Sheet
  2. >>Market Access
  3. >>Government Payers
  4. >>Medicare

US Sickle Cell Gene Therapy Contracting Demo Attracting Interest From States

 
• By Laura Helbling

The US Medicaid agency says states representing more than 80% of sickle cell patients are interested in a centralized contracting program, but House Republicans want legislation, not administrative interventions, to shape value-based payment for curative therapies.

sickle cell disease
The CMMI centralized contracting program is only focusing on sickle cell disease for now, Fowler said. • Source: Shutterstock

A US Medicaid program to test centralized contracting for sickle cell disease gene therapies has attracted widespread interest from state payors.

Key Takeaways

  • States are interested in a CMS program on centralized contracting for gene therapies treating sickle cell disease.

The US Center for Medicare and Medicaid Innovation has received letters of intent from “a majority of states that represent...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medicare

More from Government Payers

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Payment Cap Not Always Solution For Unaffordable Drugs, Maryland PDAB Director Says

 
• By Cathy Kelly

The state's Prescription Drug Affordability Board, the oldest of a growing list of the boards, chose six drugs for affordability reviews and has the authority to set a ceiling on the amount state and local government payers would reimburse for them.

Saving Part D: US Medicare Advisors Sound The Alarm

 
• By Michael McCaughan

The US Medicare Payment Advisory Commission worries that Medicare prescription drug market trends may cause the stand-alone plan portion of the program to “wither away,” which could take the traditional fee-for-service side of Medicare with it.